文献速递类风湿关节炎

类风湿关节炎生物制剂和靶向合成改善病情抗风湿药使用的时间与地区差异:一项全国性队列研究

Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

研究期内启用率略有上升(2021年5月至2022年4月为9.2%),但2021年7月指南将b/tsDMARDs启动阈值降至中重度RA后未见显著差异。地区间启用比例从威尔士的5.1%到英格兰西北部的10.7%不等,病例组合调整后医院层面ICC为0.17,地区间ICC为0.0,提示地区差异反映医院层面差异。

要点

  • 6098例RA患者中508例(8.3%)在初次评估后12个月内启用b/tsDMARDs。
  • 指南将b/tsDMARDs启动阈值降至中重度RA后,启用率无显著差异。
  • 地区启用比例从威尔士5.1%到英格兰西北部10.7%不等。

核心结论

  • 尽管有全民医疗体系,英格兰和威尔士新诊断RA患者启用b/tsDMARDs存在显著差异,需解决以实现公平可及。

研究设计与样本

  • 观察性队列研究,纳入2018年5月至2022年4月英格兰和威尔士国家早期炎症性关节炎审计中具有12个月随访数据的RA患者,共6098例。
  • 采用病例组合调整的混合效应回归评估地区和医院层面b/tsDMARDs启用的差异。

主要发现

  • 6098例RA患者中508例(8.3%)在初次风湿科评估后12个月内启用b/tsDMARDs。
  • 研究期末(2021年5月至2022年4月)b/tsDMARDs启用率为9.2%,较前略有上升。
  • 2021年7月指南允许中重度RA使用b/tsDMARDs后,启用率无显著差异。
  • 地区间启用比例从威尔士5.1%到英格兰西北部10.7%不等。
  • 病例组合调整后,医院层面ICC为0.17,地区间ICC为0.0。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate temporal and regional variation in biologic and targeted synthetic DMARD (b/tsDMARD) initiation for RA in England and Wales. METHODS: An observational cohort study was conducted for people with RA enrolled in the National Early Inflammatory Arthritis Audit (NEIAA) between May 2018 and April 2022 who had 12-month follow-up data available. Temporal trends in escalation to b/tsDMARDs within 12 months of initial rheumatology assessment were explored, including comparisons before and after publication (July 2021) of national guidelines that lowered the threshold for b/tsDMARD initiation to include moderate-severity RA. Case-mix-adjusted, mixed-effects regression was used to evaluate regional and hospital-level variation in b/tsDMARD initiation. RESULTS: Of 6098 RA patients with available follow-up, 508 (8.3%) initiated b/tsDMARDs within 12 months of initial assessment. b/tsDMARD escalation increased marginally towards the end of the study period (9.2% in May 2021/22); however, no significant differences were evident after guidelines were published permitting b/tsDMARD use for moderate-severity RA. The proportion of individuals escalated to b/tsDMARDs varied considerably between regions, ranging from 5.1% in Wales to 10.7% in North-West England. Following case-mix adjustment, the intraclass correlation (ICC) for hospitals within regions was 0.17, compared with a between-region ICC of 0.0, suggesting that the observable regional variation reflected hospital-level differences rather than systematic differences between regions themselves. CONCLUSION: There is marked variation in escalation to b/tsDMARDs for people newly diagnosed with RA throughout England and Wales, despite a universal health-care system. These disparities must be addressed if we are to deliver equitable access to b/tsDMARDs, regardless of geography.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Russell MD, Yang Z, Dooley N, et al. Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study. Rheumatology (Oxford). 2025. PMID: 39485485. doi:10.1093/rheumatology/keae607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。